Connect your AI

Climb Bio, Inc. CLYM Net Investment in Lease

Net Investment in Lease at other companies

Kyverna Therapeutics, Inc.KYTX

——

Cullinan Therapeutics, Inc.CGEM

——

Jade Biosciences, Inc. Common StockJBIO

——

Artiva Biotherapeutics, Inc.ARTV

——

Alumis Inc.ALMS

——

Dianthus TherapeuticsDNTH

——

Other financials

Income statement

Operating income-$15.2M+33.9%

Net income-$13.7M+34.0%

EPS (diluted)-$0.20+35.5%

Balance sheet

Cash & equivalents$8.4M-71.2%

Total debt$479.0K+1.1%

Total equity$148.1M-23.4%

Total assets$152.4M-24.1%

Cash flow

Operating cash flow-$14.4M+6.8%

CapEx$109.0K—

Free cash flow-$15.6M-183%

Valuation

Market cap$724.95M+787%

Enterprise value$717.07M+1,247%

Returns & leverage

Return on equity-30.9%-10.3pp

Debt / equity0×0.0×

Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Climb Bio, Inc.'s net investment in lease?: Climb Bio, Inc. (CLYM) reported net investment in lease of $447K in Q1 2026.
How has Climb Bio, Inc.'s net investment in lease changed year-over-year?: Climb Bio, Inc.'s net investment in lease decreased by 0.9% year-over-year, from $451K to $447K.